«BioEq» recruits for patients with melanoma

«BioEq» recruits for patients with nonresectable or metastatic melanoma to participate in a phase II clinical study.

Study medicationmonoclonal anti-PD-1 antibody.

Clinical study length: Maximum 69 weeks, including screening (up to 4 weeks), clinical study therapy (up to 53 weeks), further monitoring (up to 12 weeks)

We invite adult male and female patients with:

  • Histological verificate nonresectable or metastatic melanoma
  • Elementary educed frequent or metastatic melanoma
  • Disease progression after previous system therapy

Please contact us at 8-812-945-22-32 to learn more.